NCT04113837

Brief Summary

The proposed intervention study is designed to evaluate the physiological impact of the regular consumption of the developed foods with improved nutrient profile (verum) in comparison to commercial available foods (control) by a controlled, randomized, double-blind crossover study with patients with measurable cardiovascular risk factors (LDL cholesterol ≥ 120 mg/dl (≥ 3 mmol/l) / Triacylglycerides ≥ 135 mg/dl (≥ 1,5 mmol/l)).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Oct 2019

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 1, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 3, 2019

Completed
26 days until next milestone

Study Start

First participant enrolled

October 29, 2019

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 16, 2020

Completed
7 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 23, 2020

Completed
Last Updated

March 25, 2020

Status Verified

September 1, 2019

Enrollment Period

5 months

First QC Date

October 1, 2019

Last Update Submit

March 24, 2020

Conditions

Keywords

foods, nutrient profile, dietary fiber, omega 3 fatty acids

Outcome Measures

Primary Outcomes (1)

  • LDL cholesterol

    cardiovascular risk factor

    change from baseline after 4 weeks

Secondary Outcomes (34)

  • blood lipids

    change from baseline after 4 weeks

  • anthropometric data

    change from baseline after 4 weeks

  • blood pressure

    change from baseline after 4 weeks

  • lipoprotein a

    change from baseline after 4 weeks

  • high-sensitive c-reactive protein

    change from baseline after 4 weeks

  • +29 more secondary outcomes

Study Arms (2)

verum

EXPERIMENTAL

The food range is comprised of: sausages (1100 g per week / exchange of saturated fatty acids by long-chain unsaturated omega-3 fatty acids from fish oil (Maris Oil ED0222N rich in docosahexaenoic acid (DHA)), partially exchange of fat by plant protein (sesame)), eggs (3 eggs per week / 2 µg vitamin D per egg), 100 g mushrooms per day (5 µg Vitamin D/d), one bread per week (5 µg Vitamin D/d), bread rolls (16 g dietary fibers/d), 100 ml ice cream per week (exchange of sugar by xylitol), 3x 70 g pasta per week (3 x 10 g dietary fibers per week)

Dietary Supplement: food range

control

ACTIVE COMPARATOR

In the placebo period, the participants receive commercially available foods (sausages (raw, boiled and cooked varieties), eggs, mushrooms, bread, bread rolls, ice cream and pasta) with traditional nutrient profile.

Dietary Supplement: food range

Interventions

food rangeDIETARY_SUPPLEMENT

The food range is comprised of: sausages (1100 g per week) eggs (3 eggs per week), 100 g mushrooms per day, one bread per week, bread rolls, 100 ml ice cream per week, 3x 70 g pasta per week

controlverum

Eligibility Criteria

Age25 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • females and males
  • BMI \< 30 kg/m2
  • subjects must be able and willing to give written informed consent, and to comply with study procedures
  • Participants following a traditional Western diet composed of dairy products, sausage, meat, fast foods, chocolate and snacks, cereals, vegetables, and fruits (PAL: 1.6)
  • Precondition: Stable eating habits of at least one years before enrolment
  • subjects with moderate elevated LDL cholesterol (≥ 3 mmol/l) and triacylglyceride concentrations (≥ 1.5 mmol/l) in plasma, without lipid-lowering medication
  • stable dose of antihypertensive medication for \> 3 months before study and during the entire study period or without antihypertensive medication
  • subjects must have adequate fluency in the German language to complete the questionnaires and understand the nutritional recommendations

You may not qualify if:

  • subjects with any acute or chronic disease (CVD, tumor, infection, other), gastrointestinal diseases, diabetes mellitus (type I and II), chronic renal disease, diseases of the parathyroid, diseases necessitating regular phlebotomies other chronic diseases which could affect the results of the present study
  • use of prescription medicine which could affect results of the study, including systemic glucocorticoids
  • intake of lipid-lowering drugs, diabetes medication, hormone replacement therapy
  • estimated glomerular filtration (eGFR) rate \< 60 ml/min
  • weight loss (≤ 3 kg) or weight gain (≥ 3 kg) during the last three months before study begin
  • pregnancy or lactation
  • transfusion of blood in the last three months before blood sample taking
  • use of dietary supplements incl. multivitamins, fish oil capsules, minerals, and trace elements (three months before and during the entire study period)
  • vegetarians, vegans, food allergies (e.g. milk, nuts etc.)
  • dependency on alcohol or drugs
  • elite athletes (\>10 hours of strenuous physical activity per week)
  • simultaneous participation in other clinical studies
  • inability (physically or psychologically) to comply with the procedures required by the protocol

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Friedrich Schiller University

Jena, Thuringia, 07743, Germany

Location

Related Links

Study Officials

  • Christine Dawczynski, PhD

    University of Jena

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, CARE PROVIDER
Masking Details
The foods are offered in neutral packaging and are provided regularly by the study team. All personal (participants, care provider) are blinded.
Purpose
TREATMENT
Intervention Model
CROSSOVER
Model Details: The controlled, randomized, double-blind crossover study consists of a 4-week investigation periods with a 11-week wash-out period in between. At the beginning, participants are randomly allocated into the verum or the control/placebo group. After the wash-out phase the interventions are crossed between the groups and the respective food range is consumed also for four weeks.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD

Study Record Dates

First Submitted

October 1, 2019

First Posted

October 3, 2019

Study Start

October 29, 2019

Primary Completion

March 16, 2020

Study Completion

March 23, 2020

Last Updated

March 25, 2020

Record last verified: 2019-09

Data Sharing

IPD Sharing
Will not share

Locations